论文部分内容阅读
目的评价吡柔比星(THP)膀胱灌注及卡介苗(BCG)膀胱灌注预防膀胱癌术后复发的效果。方法患者随机分成两组,一组患者膀胱灌注THP(58例),另一组膀胱灌注卡介苗(54例),各组均灌注6-48个月,期间观察复发情况及不良反应。结果THP膀胱灌注组复发率为12.3%,18.96%出现不良反应症状;卡介苗膀胱灌注组复发率为9.25%,31.48%患者出现不良反应症状,两组比较BCG组疗效高于THP组,而BCG膀胱刺激症状亦高于THP组。结论THP及卡介苗均是有效的预防膀胱癌术后复发的药物,卡介苗膀胱灌注后患者1年内复发率明显低于THP组,但局部反应较大,可根据病患的具体情况应用药物。
Objective To evaluate the effect of intravesical instillation of pirarubicin (THP) and intravesical instillation of BCG on postoperative recurrence of bladder cancer. Methods The patients were randomly divided into two groups. One group received intravesical instillation of THP (58 cases) and the other group received intravesical instillation of BCG (54 cases). Each group was infused for 6 to 48 months. Recurrence and adverse reactions were observed. Results The recurrence rate of THP group was 12.3% and 18.96%, respectively. The recurrence rate was 9.25% in BCI group and 31.48% in BCG group. The BCG group had higher efficacy than THP group, Stimulation symptoms were also higher than THP group. Conclusion Both THP and BCG are effective in preventing postoperative recurrence of bladder cancer. The recurrence rate of BCG after 1-year intravesical instillation of bladder is obviously lower than that of THP group, but the local reaction is large, and the medicine can be applied according to the specific situation of the patient.